Integra LifeSciences Holdings Co. (NASDAQ:IART) Stock Position Raised by Jane Street Group LLC

Jane Street Group LLC boosted its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 269.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 224,896 shares of the life sciences company’s stock after purchasing an additional 164,083 shares during the period. Jane Street Group LLC owned 0.29% of Integra LifeSciences worth $5,101,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Northern Trust Corp increased its holdings in shares of Integra LifeSciences by 9.9% in the 4th quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company’s stock valued at $20,240,000 after purchasing an additional 80,090 shares during the period. Aquatic Capital Management LLC acquired a new position in Integra LifeSciences in the 4th quarter valued at approximately $299,000. Lord Abbett & CO. LLC lifted its position in Integra LifeSciences by 86.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock worth $30,210,000 after buying an additional 618,773 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Integra LifeSciences by 10.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 47,090 shares of the life sciences company’s stock valued at $1,069,000 after buying an additional 4,452 shares during the period. Finally, State of Tennessee Department of Treasury grew its holdings in shares of Integra LifeSciences by 34.7% during the 4th quarter. State of Tennessee Department of Treasury now owns 23,381 shares of the life sciences company’s stock valued at $530,000 after acquiring an additional 6,026 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 5.0 %

Integra LifeSciences stock opened at $12.25 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a fifty-two week low of $11.60 and a fifty-two week high of $32.66. The firm has a fifty day moving average price of $18.93 and a two-hundred day moving average price of $21.88. The firm has a market cap of $951.97 million, a price-to-earnings ratio of -136.10, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). The business had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 EPS. As a group, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IART. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. JMP Securities reduced their price target on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a report on Friday. JPMorgan Chase & Co. dropped their price objective on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, May 6th. Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Finally, Wells Fargo & Company dropped their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. Four analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.